If you've spent any time in GLP-1 forums, you've seen the anxiety. Someone posts a before-and-after photo and the comments flood in — "You look great, but did you lose muscle too?" It's become one of the most discussed concerns around these medications, and it deserves a thorough, honest answer.
So let's start with the data, not the fear.
What the clinical trials actually show
The SURMOUNT-1 body composition substudy used DXA scanning — the gold standard for measuring fat versus lean mass — on participants taking tirzepatide. The finding: approximately 75% of total weight lost was fat mass. The remaining 25% was lean mass, which includes muscle, water, and other non-fat tissue (Look et al., 2025).
Is that concerning? It depends on context.
When anyone loses significant weight — through dieting, surgery, illness, or medication — lean mass loss comes with it. A ratio of 25% lean to 75% fat is actually within normal physiological ranges for weight loss. It's not unique to GLP-1 medications. A recent systematic review of tirzepatide studies specifically concluded that the drug showed "relative preservation of lean mass" compared to the degree of weight loss achieved (Ramos et al., 2025).
Even more interesting was the SURPASS-3 MRI substudy, which looked beyond raw mass and examined muscle quality. Participants on tirzepatide showed a significant decrease in muscle fat infiltration — essentially, the fat within their muscles decreased. Researchers compared this to population data from the UK Biobank and found that tirzepatide actually counteracted the natural age-related increase in muscle fat. The muscle volume loss was proportional to what you'd expect from the weight lost, but the muscle quality improved (Sattar et al., 2025).
Put differently: the muscle got smaller, but it also got healthier. That nuance matters enormously and rarely makes it into the headlines.
Real-world data paints a similarly nuanced picture. A study tracking fat mass and lean mass over time found that lean mass dipped early in treatment, then stabilised. Importantly, handgrip strength — a direct measure of functional muscle capacity — actually improved, and rates of sarcopenic obesity decreased (Alissou et al., 2025).
Why this still matters
None of that means muscle loss is trivial. It isn't. Muscle is your metabolic engine, your functional foundation, your insurance policy against ageing. Lose too much and you get a slower metabolism (making regain more likely), reduced physical capability, the "skinny fat" appearance that nobody wants, and increased injury risk as you age.
The point isn't to dismiss the concern. It's to understand it accurately so you can address it effectively.
The muscle preservation protocol
This isn't complicated, but it is non-negotiable. If you're taking a GLP-1 medication and not doing these things, you're leaving muscle on the table.
Resistance training comes first. Not walking. Not yoga. Not a spin class. Those are fine additions, but the single most powerful signal you can send your body to preserve muscle during a caloric deficit is progressive resistance training — lifting heavy things, putting them down, and doing it heavier next time.
A simple, effective structure that one of our team follows: train three to four times per week, focusing on compound movements that work multiple muscle groups simultaneously. Squats, deadlifts, bench press, rows, overhead press, pull-ups. These movements recruit the most muscle mass and produce the strongest adaptive signal.
You don't need a fancy gym. You don't need machines. A barbell, some dumbbells, or even bodyweight progressions can get the job done. What matters is that you're challenging your muscles close to their limits on a regular schedule, and that the challenge increases over time. That progressive overload is the stimulus that tells your body "this muscle is needed — don't metabolise it for energy."
Protein is your most important nutrient. On a GLP-1 medication with suppressed appetite, every gram of food you eat has to earn its place. Protein earns that place more than anything else.
Target 1.6 to 2.2 grams per kilogram of your goal body weight. If you're aiming for 75kg, that's 120 to 165 grams of protein daily. That is difficult when you're eating 1,400 calories a day and your appetite barely lets you finish half a chicken breast.
This is where practical strategy matters. Eat protein first at every meal — before the vegetables, before the carbohydrates. When your stomach fills fast, you need the most important nutrient to get in first. Use protein supplements strategically: a whey isolate shake blended with Greek yoghurt can deliver 40-50 grams of protein when solid food feels like too much effort. Hard-boil a dozen eggs on Sunday and keep them in the fridge. These small tactics make the difference between hitting your target and falling short.
Don't crash your calories. The medication suppresses your appetite. You don't need to stack extreme restriction on top. Eating too little — consistently under 1,200 calories — accelerates muscle loss regardless of what medication you're taking. Aim for a moderate deficit. If you find yourself regularly eating under 1,000 calories because your appetite has vanished, talk to your doctor. That level of intake is difficult to sustain nutritionally and will cost you muscle.
Sleep matters more than most people think. Growth hormone — essential for muscle maintenance and repair — is primarily released during deep sleep. Poor sleep has been directly linked to increased muscle loss during caloric restriction. Seven to nine hours. Consistent schedule. Dark room. No negotiation.
Consider creatine monohydrate. Five grams daily. It's one of the most studied supplements in existence, with decades of safety data and consistent evidence of supporting muscle strength and preservation during caloric restriction. It's cheap, effective, and has no meaningful interaction with GLP-1 medications.
A note on cardio
Cardiovascular exercise matters for heart health, mood, and general fitness. But when muscle preservation is the goal, be thoughtful about balance.
Excessive steady-state cardio — long runs, hours on a bike — combined with a caloric deficit and GLP-1-driven appetite suppression can create a catabolic environment that accelerates muscle loss. A better approach: prioritise resistance training, then layer moderate cardio around it.
Walking is arguably the best cardiovascular exercise for someone on a GLP-1 medication. It burns meaningful calories over time, doesn't significantly impact muscle recovery, aids digestion (helpful for GLP-1 side effects), and you can do it every day without compromising your next training session.
The honest bottom line
Losing some lean mass on a GLP-1 medication is physiologically normal and proportional to the weight loss achieved. The data is more reassuring than the headlines suggest — muscle quality may actually improve, functional strength can be maintained or even gained, and the 75/25 fat-to-lean ratio is consistent with what you'd see from any method of weight loss.
But "normal" doesn't mean "acceptable without intervention." The people who come out the other side of GLP-1 treatment looking and feeling their best are the ones who train with resistance, eat enough protein, sleep properly, and don't try to lose weight as fast as humanly possible.
The medication handles the appetite. You handle the muscle. That's the deal.
Key Studies & References
We base this guide on the strongest available peer-reviewed research so you can see exactly where the information comes from. Here are the most relevant and impactful studies we referenced:
-
Look et al. (2025) — DXA body composition substudy of SURMOUNT-1 showing approximately 75% of weight lost on tirzepatide is fat mass with 25% lean mass, consistent across subgroups — the foundational data point for understanding muscle loss on GLP-1 medications. Read the study on PubMed
-
Sattar et al. (2025) — MRI substudy of SURPASS-3 showing tirzepatide reduced muscle fat infiltration significantly while muscle volume changes were proportional to weight loss — suggesting muscle quality actually improves even as volume decreases. Read the study on PubMed
-
Ramos et al. (2025) — Systematic review of all available tirzepatide skeletal muscle studies, concluding that the drug shows "relative preservation of lean mass" compared to the degree of weight loss achieved. Read the systematic review on PubMed
-
Alissou et al. (2025) — Real-world study tracking body composition over time on semaglutide: lean mass dipped early then stabilised, handgrip strength improved, and sarcopenic obesity decreased — showing functional muscle capacity can be maintained. Read the study on PMC
-
Bikou et al. (2024) — Systematic review specifically examining semaglutide's effects on lean mass, providing a balanced overview of concerns versus the reassuring clinical data. Read the review on PubMed
-
Wilding et al. (2021) — STEP 1 body composition substudy using DXA data showing semaglutide reduced fat mass more than lean mass, with the lean-to-fat ratio improving with greater weight loss. Read the study on PMC
These studies consistently show that muscle loss during GLP-1 treatment is proportional to overall weight loss — not excessive — and that muscle quality may actually improve. However, they also underscore why resistance training and adequate protein intake are essential components of treatment.
Medical Disclaimer: This guide is for informational purposes only. Consult your healthcare provider or a qualified exercise professional before starting any exercise programme while on GLP-1 medications.